Thiazolidinediones are peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, which are under investigation for use as synergizing co-treatment together with TKI in CML. This evidence concerns the gene PPARG and chronic myelogenous leukemia, BCR-ABL1 positive.